Cargando…
Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695233/ https://www.ncbi.nlm.nih.gov/pubmed/19557122 |
_version_ | 1782168174421082112 |
---|---|
author | Muzina, David J |
author_facet | Muzina, David J |
author_sort | Muzina, David J |
collection | PubMed |
description | Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered. |
format | Text |
id | pubmed-2695233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26952332009-06-16 Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole Muzina, David J Neuropsychiatr Dis Treat Expert Opinion Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered. Dove Medical Press 2009 2009-05-20 /pmc/articles/PMC2695233/ /pubmed/19557122 Text en © 2009 Muzina, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Expert Opinion Muzina, David J Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
title | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
title_full | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
title_fullStr | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
title_full_unstemmed | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
title_short | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
title_sort | treatment and prevention of mania in bipolar i disorder: focus on aripiprazole |
topic | Expert Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695233/ https://www.ncbi.nlm.nih.gov/pubmed/19557122 |
work_keys_str_mv | AT muzinadavidj treatmentandpreventionofmaniainbipolaridisorderfocusonaripiprazole |